8-K: Hims & Hers Health, Inc. Reports Strong Q4 and Full Year 2024 Results, Revenue Surges 69% to $1.5 Billion

Hims & Hers Health, Inc. announces impressive financial results for 2024, with revenue reaching $1.5 billion, a 69% increase year-over-year, driven by subscriber growth and the expansion of its weight loss offerings.

Summary

• Hims & Hers Health, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company's revenue for 2024 reached $1.5 billion, marking a 69% increase compared to the previous year.
• Net income for 2024 was $126 million, a significant improvement from the net loss of $(23.5) million in 2023.
• Adjusted EBITDA for 2024 was $177 million, up from $49.5 million in the prior year.
• The company's subscriber base grew to 2.2 million, a 45% increase year-over-year.
• For Q1 2025, the company expects revenue of $520 million to $540 million and Adjusted EBITDA of $55 million to $65 million.
• For the full year 2025, revenue is projected to be in the range of $2.3 billion to $2.4 billion, with Adjusted EBITDA between $270 million and $320 million.

Sentiment

Score: 9

Explanation: The document expresses a highly positive sentiment due to the company's strong financial performance, subscriber growth, and optimistic outlook for the future. The management's comments and strategic initiatives further contribute to the positive sentiment.

Positives

• Significant revenue growth of 69% year-over-year, reaching $1.5 billion in 2024.
• Return to profitability with a net income of $126 million in 2024.
• Substantial increase in Adjusted EBITDA, reaching $177 million in 2024.
• Strong subscriber growth, expanding the base to 2.2 million.
• Positive financial outlook for 2025, with projected revenue between $2.3 billion and $2.4 billion.
• The company has over $300 million of cash, cash equivalents, and short-term investments and no debt on the balance sheet.
• Marketing expenses decreased from 51% to 46% of revenue during both the fourth quarter and full year.
• Free cash flow increased to $198.3 million for the year ended December 31, 2024.

Negatives

• Gross margin decreased from 83% to 77% in the fourth quarter of 2024.
• The FDA resolved the semaglutide shortage, which could constrain the ability to continue providing access to compounded semaglutide on the platform once current inventory has been sold.

Risks

• The company's future performance is subject to various risks and uncertainties, including regulatory changes and market conditions.
• The forward-looking statements are based on current expectations and beliefs, but actual results may differ materially due to various factors.
• The company's ability to comply with extensive, complex, and evolving legal and regulatory requirements applicable to its business is a risk.
• The FDA's resolution of the semaglutide shortage could constrain the company's ability to provide access to compounded semaglutide.

Future Outlook

Hims & Hers expects revenue of $2.3 billion to $2.4 billion and Adjusted EBITDA of $270 million to $320 million for the full year 2025.

Management Comments

• Andrew Dudum, co-founder and CEO, stated that 2024 was a fantastic year and that the company continues to build a platform that leverages personalization and technology unlike any traditional healthcare system.
• Yemi Okupe, CFO, stated that the company's success is a direct reflection of its improving ability to democratize access to high quality, personalized care across each of its specialties.

Industry Context

Hims & Hers is positioning itself as a leader in the telehealth and wellness space by offering personalized and accessible healthcare solutions, including expanding into high-demand areas like weight loss. The company's focus on technology and data-driven insights aligns with the broader trend of digital transformation in healthcare.

Comparison to Industry Standards

• Hims & Hers' subscriber growth of 45% year-over-year demonstrates strong market traction compared to traditional healthcare providers.
• The company's Adjusted EBITDA margin of 12% for 2024 indicates efficient operations and profitability compared to other telehealth companies.
• Hims & Hers' expansion into weight loss solutions and personalized treatments positions it competitively against companies like Teladoc Health and Ro.
• The company's focus on affordability and accessibility differentiates it from traditional healthcare models and aligns with the growing demand for convenient and cost-effective healthcare options.

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance and growth prospects.
• Employees will have opportunities for growth and development within the expanding company.
• Customers will gain access to a wider range of personalized and affordable healthcare solutions.
• Suppliers will benefit from increased demand for products and services.
• Creditors will have confidence in the company's ability to meet its financial obligations.

Next Steps

• The company will focus on positioning its weight loss specialty as a durable market leader.
• Hims & Hers plans to integrate and leverage lab diagnostic capabilities to enrich data and strategic insights.
• The company will invest in affiliated pharmacies to increase the breadth of personalized treatments.
• Hims & Hers will set the foundation for expansion into new specialties.
• The company aims to expand the depth of technological capabilities available to consumers and providers.

Key Dates